X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CTL-002 (Visugromab) is a monoclonal antibody that neutralizes the tumor-derived Growth Differentiation Factor-15 (GDF-15) in combination with neoadjuvant immunotherapy (nivolumab, aPD-1 inhibitor) in muscle invasive bladder cancer (MIBC).
Lead Product(s): Visugromab,Nivolumab
Therapeutic Area: Oncology Product Name: CTL-002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
The financing will support the continued, promising clinical development of its lead candidate, visugromab, a humanized monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15).
Lead Product(s): Visugromab,Nivolumab
Therapeutic Area: Oncology Product Name: CTL-002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Brandon Capital
Deal Size: $51.8 million Upfront Cash: Undisclosed
Deal Type: Series C Financing November 22, 2022
Details:
Visugromab, formerly known as CTL-002, is a monoclonal antibody that neutralizes GDF-15, a key immunosuppressor, which has been shown to prevent T cell migration into tumors, enabling cancerous cells to evade the immune system.
Lead Product(s): Visugromab,Nivolumab
Therapeutic Area: Oncology Product Name: CTL-002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2022
Details:
Visugromab, formerly known as CTL-002, is a humanized, monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15).
Lead Product(s): Visugromab,Nivolumab
Therapeutic Area: Oncology Product Name: CTL-002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2022
Details:
Visugromab, formerly known as CTL-002, is a humanized, monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15).
Lead Product(s): Visugromab,Nivolumab
Therapeutic Area: Oncology Product Name: CTL-002
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2022
Details:
The GDFATHER-2 trials, will evaluate safety and efficacy of CTL-002, mAB designed to neutralize tumor-produced GDF-15, at confirmed target dose in combination with nivolumab in tumor patients to anti-PD1/-L1 treatment and in one cohort that is anti-PD-1/-L1 naive.
Lead Product(s): Visugromab,Nivolumab
Therapeutic Area: Oncology Product Name: CTL-002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
CatalYm’s CTL-002 demonstrate clinical proof-of-concept in multiple solid tumor indications which will expand the treatment for current and future immunotherapies. CTL-002 is a humanized, monoclonal antibody designed to neutralize the tumor-produced GDF-15.
Lead Product(s): CTL-002
Therapeutic Area: Oncology Product Name: CTL-002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2021
Details:
CTL-002 is a humanized, monoclonal antibody designed to neutralize tumor-produced Growth Differentiation Factor-15 by enhancing infiltration of immune cells into tumor, improving both priming of T cells by dendritic cells and tumor killing by T cells and NK cells.
Lead Product(s): CTL-002
Therapeutic Area: Oncology Product Name: CTL-002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
Details:
CatalYm’s lead molecule CTL-002 was specifically designed to neutralize a tumor-produced protein called GDF-15. CTL-002 addresses three of the tumor’s immune suppressive mechanisms all involving the inhibitory effect of GDF-15 on the immunostimulatory LFA-1/ICAM-1 interaction.
Lead Product(s): CTL-002
Therapeutic Area: Oncology Product Name: CTL-002
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Vesalius Biocapital III
Deal Size: $61.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
